Research programme: neurogenesis therapeutics - Newron Sweden

Drug Profile

Research programme: neurogenesis therapeutics - Newron Sweden

Alternative Names: sNN 0126; sNN 0465

Latest Information Update: 13 Sep 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuroNova AB
  • Developer Newron Sweden AB
  • Class Nerve growth factors; Peptides; Proteins; Small molecules
  • Mechanism of Action Neuron stimulants; Neuropilin-1 inhibitors; Platelet-derived growth factor receptor agonists; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Amyotrophic lateral sclerosis; Huntington's disease; Major depressive disorder; Neurological disorders; Parkinson's disease

Most Recent Events

  • 13 Sep 2013 Discontinued - Preclinical for Alzheimer's disease in Sweden (unspecified route)
  • 13 Sep 2013 Discontinued - Preclinical for Amyotrophic lateral sclerosis in Sweden (Intracerebro-ventricular)
  • 13 Sep 2013 Discontinued - Preclinical for Huntington's disease in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top